DOCSLIB.ORG

Glaucoma: Etiology, Pathophysiology and Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glaucoma: Etiology, Pathophysiology and Management Mini Review ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.30.005005 Glaucoma: Etiology, Pathophysiology and Management Shahida*and Muhammad Imran Qadir Institute of Molecular Biology & Biotechnology, Multan, Pakistan *Corresponding author: Shahida, Institute of Molecular Biology & Biotechnology, Multan, Pakistan ARTICLE INFO ABSTRACT Received: September 17, 2020 Glaucoma is a steady degeneration of retinal ganglion cells (RGCs) and optic nerves axons. 66 million people are worldwide affected by the glaucoma. Based on Published: September 29, 2020 glaucoma. Several factors contributing to glaucoma are increased intraocular pressure Citation: Shahida, Muhammad (IOP),pathophysiology, Migraine anatomyheadache, glaucoma family history,is classified systemic as close-angle hypertension. glaucoma Severe and open-angle eye pain, Imran Qadir. Glaucoma: Etiology, headache, nausea, vomiting and visual blurring are the main symptoms of glaucoma. Pathophysiology and Management. Tonometry, Pachymetry, Gonioscopy are some of the tests used for the analysis of glaucoma. Different treatments are now available to treat glaucoma. BJSTR. MS.ID.005005. Keywords: Biomed J Sci & Tech Res 30(5)-2020. Pachymetry; Gonioscopy Glaucoma;Close-Angle Glaucoma; Open-Angle Glaucoma; Tonometry; Introduction Glaucoma is a gradual degeneration of retinal ganglion cells (RGCs) and optic nerves axons. Retinal ganglion cells are the neuron Americans and in African Americans 67%. Optic nerve damage at cells of central nervous system, cell bodies of neurons are present earlier age is contributing to high prevalence in African Americans. glaucoma (start up to the age of three years), juvenile open angle in the interior retina and their axons are present in optic nerve. Based on age of onset POAG is characterized as primary congenital of glaucoma are still not fully understood. Main reason yet known glaucoma (JOAG initiate at age is 3-5 years) and adult onset POAG[1]. Actual Biological basis and factors contributing to the progression for glaucoma is the increased intraocular pressure within the eye, which is responsible of the degeneration of retinal ganglion cells and nerve cells. 66 million people are affected by the glaucoma worldwide. Several factors contributing to glaucoma are increased intraocular pressure (IOP), Migraine headache, family history, systemic hypertension, high myopia, cardiovascular disease, prior nerve damage, peripheral vasospasm, Visual damage caused by glaucoma is irreversible. Blindness is induced by neuronal cell death which leads to increased IOP. Figure 1: Increased IOP and optic nerve damage. Glaucoma is classified based on pathophysiology, anatomy as close-angle glaucoma and open-angle glaucoma. Both close-angle ensuing in idiopathic or primary glaucoma. The type of glaucoma and open-angle glaucoma can occur with no identifiable cause, defect, increased IOP and morphological loss of optic disk as shown Primary open angle glaucoma is caused due to visual field in Figure 1. In early stage of glaucoma peripheral vision is affected which has an identifiable cause of elevated IOP, resulting in optic and central vision is resistant to glaucoma. Changes in peripheral nerve damage is referred as secondary glaucoma e.g. Pseudo- exfoliative glaucoma. Primary Open –angle glaucoma (POAG) is vision area can be identified by visual field testing and selective a frequent type of glaucoma with 0.58% occurrence rate in Asia Copyright@ Shahida | Biomed J Sci & Tech Res | BJSTR. MS.ID.005005. 23695 Volume 30- Issue 5 DOI: 10.26717/BJSTR.2020.30.005005 perimetry. Structural changes (loss of macular ganglion cells and Glaucoma and it is also linked to genetic mutations. There are with glaucoma. One third of POAG is comprised of normal tension imaging techniques.Open angle glaucoma is not described by the 6 % chances of glaucoma to be occur in a person having family retinal nerve fiber layer [RNFL] can be detected by the optic nerve Mendelian mode of inheritance rather it involves multiple genes. In Differenthistory[7]. Types of Glaucoma genes. Primary open angle glaucoma is associated with genomic contrast, Reiger’s syndrome congenital glaucoma involves specific mutations for example myocilin, shows autosomal dominant Open-Angle Glaucoma Primary Chronic Open Angle Glaucoma (COAG) world. Therapeutic decision can be easily done after determining pattern of inheritances leading to 2-4% of open angle glaucoma in It is frequent type of glaucoma. The occurrence of COAG elevates Pathophysiologythe disease stage and of its Open progression[2]. Angle Glaucoma with age. Along with the aging process the drainage system of eye is disturbed. Without any symptoms or pain pressure builds up In Glaucoma, the loss of retinal ganglion cells is linked to gradually gets clogged. As a result, the proper drain of aqueous fluid with in the eye, results to initiate the loss of vision of peripherally intraocular pressure. Intraocular pressure is determined through the balance between secretion of aqueous humor by the ciliary body and its drainage through independent pathways the uveoscleral Congenitalof eye[7]. (Infantile) Glaucoma produces mechanical stress on the posterior structure of eyes, results because of improper development of drainage area before outflow pathway and trabecular meshwork. Intraocular pressure It is uncommon and inherited type of open-angle glaucoma. It lamina cribrosa and its adjacent tissues.Glaucoma makes the sclera birth. Consequently, the pressure in eye is increased that lead to vision loss. In this condition the increased pressure and optic nerve perforated at lamina; this is a point at which optic nerve fibers of applied by the intraocular pressure may lead to deformation, the eye exit. Lamina is a delicate point of pressurized eye. Stress compression, mechanical axonal damage, remolding of the Normaldamage lead Tension to loss of(Pressure) vision[7]. Glaucoma or Low-Tension lamina cribrosa, disruption of axonal transport. Oxidative stress Glaucoma excitotoxicity altered immunity and impaired microcirculation may It may be caused by decreased flow of blood to the optic nerve Causescause glaucoma[3]. of Glaucoma fibers of the eye. This situation is specified as the continuous damage to optic-nerve and lack of peripheral vision (visual field) Glutamate Excitotoxicity Secondary[7]. Open-Angle Glaucoma In Glaucoma, high concentration of glutamate is observed It is a form of open angle glaucoma, which may result due to in the inner portion of the eye. Receptors of glutamate are either topical steroids. Retinal detachment or retinal vein blockage may iris inflammation, eye damage, and cataract, use of systemic or Disruptedionotropic or Transport metabotropic of (mGluR)[4].Neurotrophic Factors Death of neurons, growth and differentiation of neurons Exfoliativebe associated Glaucoma with secondary (Pseudo-exfoliation) open-angle glaucoma[7]. is regulated by neurotrophins or neurotrophic factors (NTF). of the central nervous system and increase IOP may disrupt their It is another form of glaucoma, which is identified as by the Neuotrophic factors are polypeptides originated from calliculus capsule) and in the angle of the eye. Elevated eye pressure and deposits of flaky material on anterior surface of lens (anterior blockage of drainage of the eye is supposed to be caused by the transport. NTF are produced locally in the lamina, retina, optic These factors bind and phosphorylate the Trk receptors and cause nerve body and cribosa. Decrease in NTF results in RGC apoptosis. Signgathering and of Symptoms flaky material in the angle[7]. Neuronantiapoptotic Protection effect[5]. angle glaucoma generally have no symptoms. Infrequently patients In early stages of chronic angle-closure glaucoma and open- of variable levels of intraocular pressure might have lack of clarity pathogenic agents and destroy damaged cells, referred to as T-cells protection axonal injury of neurons by removing protective immunity. Survival of neuron in increased IOP condition are severe eye pain, nausea, headache, visual blurring and vomiting. of vision, particularly in morning. In acute angle-closure symptoms In congenital glaucoma symptoms which are usually observed in Geneticmay be possible Causes by the activity of T-cells[6]. few months old child is red eye, Cloudiness of the front of the eye, Glaucoma is associated with genetic/congenital eye sensitivity to light, tearing and Enlargement of one eye or both malformations. Mutations at several loci of genes are associated eyes[7]. Copyright@ Shahida | Biomed J Sci & Tech Res | BJSTR. MS.ID.005005. 23696 Volume 30- Issue 5 DOI: 10.26717/BJSTR.2020.30.005005 Diagnostic Test for Glaucoma Tonometry Carbonic anhydrase inhibitors, Miotics, Epinephrineare utilized The pressure induced by IOP in the eye can be determined by Drugsalong with Used other in medicines Glaucoma to reduce eye pressure[7]. Drugs used to treat glaucoma are: this test there are different types of tonometer’s, most common estimating the firmness of eye surface through this technique. For Sympathomimetics anesthetic eye drops, then tonometer’s sensor is placed against a) Epinephrine is application tonometer. In this analysis eye is first treated with the front surface of the eye and the pressure in the eye can be b)c) ApraclonidinClonidin Pachymetrydetermined[7]. d) Brimonidine It is one of a latest test for the analysis and treatment of Parasympathomimetics drops treatment, tip of the pachymeter is touched lightly to the a) Muscarinic glaucoma. It checks the cornea thickness.
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Antiglaucoma Compositions Containing Combinations of Alpha-2 Agonists and Beta-Blockers
    ~" ' MM II II II MM II II II Ml II II I II J European Patent Office _ _ _ © Publication number: 0 365 662 B1 Office europeen* des.. brevets , © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 09.03.94 © Int. CI.5: A61 K 31/47 © Application number: 89905874.7 @ Date of filing: 26.04.89 © International application number: PCT/US89/01994 © International publication number: WO 89/10126 (02.11.89 89/26) (54) ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF ALPHA-2 AGONISTS AND BETA-BLOCKERS. ® Priority: 26.04.88 US 186504 1075-1078 @ Date of publication of application: J. of Cardiovascular Pharmacology, vol. 2, 02.05.90 Bulletin 90/18 suppl. 1, 1980, S. 21-28 © Publication of the grant of the patent: © Proprietor: ALCON LABORATORIES INC 09.03.94 Bulletin 94/10 6201 South Freeway Ft. Worth, TX 76134(US) © Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE @ Inventor: DE SANTIS, Louis, M. 2316 Wlnton Terrace West © References cited: Fort Worth, TX 761 09(US) US-A- 4 455 317 US-A- 4 515 800 © Representative: Jump, Timothy John Simon et AM A DRUG EVALUATION, 2nd ed., 1973; al "Agent used to treat Glaucoma", pp. 675-686. Venner Shipley & Co. 20 Little Britain GLAUCOMA, vol. 1, no. 1, February 1979; London EC1A 7DH (GB) 00 S.SUGAR, pp. 9-15. CM CO Ophthalmology, vol. 96, no. 1, 1989, p. 3-7 CO m Ophthalmology, vol. 98, no. 7, 1991, p. CO 00 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • REMEDY for GLAUCOMA COMPRISING Rho KINASE INHIBITOR and -BLOCKER
    Europäisches Patentamt *EP001568382A1* (19) European Patent Office Office européen des brevets (11) EP 1 568 382 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: A61K 45/06, A61K 31/138, 31.08.2005 Bulletin 2005/35 A61K 31/343, A61K 31/353, A61K 31/437, A61K 31/4409, (21) Application number: 03772800.3 A61K 31/4412, A61K 31/496, (22) Date of filing: 17.11.2003 A61K 31/5377, A61K 31/551, A61P 27/06, A61P 43/00 (86) International application number: PCT/JP2003/014559 (87) International publication number: WO 2004/045644 (03.06.2004 Gazette 2004/23) (84) Designated Contracting States: • NAKAJIMA, Tadashi AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Ikoma-shi, Nara 630-0101 (JP) HU IE IT LI LU MC NL PT RO SE SI SK TR • MATSUGI, Takeshi Designated Extension States: Ikoma-shi, Nara 630-0101 (JP) AL LT LV MK • HARA, Hideaki Ikoma-shi, Nara 630-0101 (JP) (30) Priority: 18.11.2002 JP 2002333213 (74) Representative: Peaucelle, Chantal et al (71) Applicant: SANTEN PHARMACEUTICAL CO., Cabinet Armengaud Ainé LTD. 3, avenue Bugeaud Osaka 533-8651 (JP) 75116 Paris (FR) (72) Inventors: • HATANO, Masakazu Ikoma-shi, Nara 630-0101 (JP) (54) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER (57) A subject of the present invention is to find utility of a co mbination of a Rho kinase inhibitor having a novel action and a β-blocker as a therapeutic agent for glau- coma.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Phvwp Monthly Report June 2011
    30 June 2011 EMA/CHMP/PhVWP/486894/2011 Patient Health Protection Monthly report Issue number: 1106 Pharmacovigilance Working Party (PhVWP) June 2011 plenary meeting The CHMP Pharmacovigilance Working Party (PhVWP) held its June 2011 plenary meeting on 20-22 June 2011. Safety concerns Discussions on non-centrally authorised medicinal products are summarised below in accordance with the PhVWP publication policy. The positions agreed by the PhVWP for non-centrally authorised products form recommendations to Member States. For the publication policy, readers are referred to http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/10/WC500006181.pdf. The PhVWP also provides advice to the Committee for Medicinal Products for Human Use (CHMP) on centrally authorised products and products subject to ongoing CHMP procedures at the request of the CHMP. For safety updates concerning these products, readers are referred to the CHMP monthly report (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document _listing_000190.jsp). Beta-blockers for ophthalmic use – Risk of systemic adverse reactions The PhVWP recommends harmonisation of product information across the EU for ophthalmic beta-blockers with regard to systemic adverse reactions. The PhVWP identified major differences in the summaries of product characteristics of beta-blockers authorised in the EU for ophthalmic use regarding the information on possible systemic effects between the different carteolol-containing ophthalmic products as well as in comparison
    [Show full text]
  • Achievements and Limits of Current Medical Therapy of Glaucoma
    Bettin P, Khaw PT (eds): Glaucoma Surgery. 2nd, revised and extended edition. Dev Ophthalmol. Basel, Karger, 2017, vol 59, pp 1–14 ( DOI: 10.1159/000458482 ) Achievements and Limits of Current Medical Therapy of Glaucoma Pelagia Kalouda · Christina Keskini · Eleftherios Anastasopoulos · Fotis Topouzis Laboratory of Research and Clinical Applications in Ophthalmology, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki , Greece Abstract ery systems are being investigated to open new horizons Prescribing medical therapy for the treatment of glauco- in glaucoma management. Although the general rule is ma can be a complex process since many parameters to initiate glaucoma management with medical treat- should be taken into consideration regarding its achieve- ment, the limits of medical therapy should be considered ments and limits. Today, a variety of options, including to identify those patients in need of surgical manage- multiple drug classes and multiple agents within classes, ment. © 2017 S. Karger AG, Basel are available to the clinician, but caution should be given to their side effects and contraindications. Glaucoma pa- tients with preexisting ocular surface disease should be State of the Art treated with caution, and preferably with preservative- free formulations, as there is an increased risk for symp- Glaucoma is a medical term describing a group of tom deterioration. The development and use of progressive optic neuropathies characterized by fixed-combination therapies has reduced the preserva- the degeneration of retinal ganglion cells and of tive-related side effects that threaten patient adherence the retinal nerve fiber layer, resulting in changes and has minimized the washout effect of multiple instil- in the optic nerve head.
    [Show full text]
  • Short-Term Effect of Topical Antiglaucoma Medication on Tear-Film Stability, Tear Secretion, and Corneal Sensitivity in Healthy Subjects
    Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects Naim Terai Background: The purpose of this study was to investigate the short-term effect of topical Matthias Müller-Holz antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy Eberhard Spoerl subjects. Lutz E Pillunat Methods: In this prospective, double-blind crossover trial, break-up time and basal secretion (Jones test) were measured 60 minutes before, and 30, 60, and 90 minutes after topical Department of Ophthalmology, Carl Gustav Carus University Hospital, antiglaucoma drop application in 30 healthy subjects. Corneal sensitivity was measured Dresden, Germany 60 minutes before, and five, 10, and 15 minutes after drop application using a Cochet–Bonnet esthesiometer. Results: Reduction of break-up time in the latanoprost group was -23.8% after 30 minutes (P = 0.21), -26.7% after 60 minutes (P = 0.03) and -51.4% after 90 minutes (P # 0.003), which was statistically significant. Reduction of break-up time in all other treatment groups was not statistically significant. The Jones test revealed a significant reduction of basal secretion after application of brimonidine (-17.8%, P = 0.002; -22.5%, P , 0.001; -30.5%, P , 0.001), fol- lowed by apraclonidine (-10%, P = 0.06; -20.1%, P = 0.02; -22.1%, P = 0.002), latanoprost (-2.4%, P = 0.64; -18.6%, P = 0.001; -20.1%, P = 0.001) and dorzolamide (-0.5%, P = 0.9; 14.3%, P = 0.018; -17.3%, P = 0.004) at 30, 60, and 90 minutes after drop application.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Periorbital Dermatitis As a Side Effect of Topical Dorzolamide Y M Delaney, J F Salmon, F Mossa, B Gee, K Beehne, S Powell
    378 SCIENTIFIC CORRESPONDENCE Br J Ophthalmol: first published as 10.1136/bjo.86.4.378 on 1 April 2002. Downloaded from Periorbital dermatitis as a side effect of topical dorzolamide Y M Delaney, J F Salmon, F Mossa, B Gee, K Beehne, S Powell ............................................................................................................................. Br J Ophthalmol 2002;86:378–380 Aim: To report periorbital dermatitis as a late side effect of topical dorzolamide hydrochloride (Trusopt), a drug used to reduce intraocular pressure. Methods: A retrospective study of 14 patients who devel- oped periorbital dermatitis while using topical dorzola- mide hydrochloride was undertaken. Six patients underwent patch testing for sensitivity to Trusopt, dorzola- mide hydrochloride, and the preservative benzalkonium chloride. Results: The periorbital dermatitis occurred after a mean period of 20.4 weeks of commencing dorzolamide hydro- β chloride therapy. 13 patients had used preserved topical Figure 1 Case 14. Marked dermatitis of the left lower lid and blocker treatment for a mean period of 34.2 months with- periorbital area, which resolved on discontinuing topical out complication before the introduction of dorzolamide. In dorzolamide. eight (57.1%) the dermatitis resolved completely after dis- continuing dorzolamide but in six (42.9%) resolution of the dermatitis did not occur until the concomitant preserved β blocker was stopped and substituted with preservative free drops. Patch testing for sensitivity to Trusopt, dorzolamide hydrochloride, and benzalkonium chloride was negative. Conclusion: These findings suggest that dorzolamide can cause severe periorbital dermatitis. Although the dermatitis may resolve when dorzolamide is discontinued, this does http://bjo.bmj.com/ not always occur and in some patients all topical medication containing benzalkonium chloride needs to be stopped.
    [Show full text]